New therapies on the horizon for hepatitis C: are we close? (Q35105724)

6 August 2017

1 reference

title

New therapies on the horizon for hepatitis C: are we close? (English)

1 reference

6 August 2017

1 reference

2

Charles M Rice

1 reference

6 August 2017

author name string

Raffaele De Francesco

series ordinal

1

1 reference

6 August 2017

publication date

1 February 2003

1 reference

6 August 2017

published in

Clinics in liver disease

1 reference

6 August 2017

volume

7

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

211-42, xi

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Efficient initiation of HCV RNA replication in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Effect of alpha interferon on the hepatitis C virus replicon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Mechanism of action of ribavirin in the combination treatment of chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Replication of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

In search of hepatitis C virus receptor(s).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

A mechanism for initiating RNA-dependent RNA polymerization

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

cis-acting RNA elements required for replication of bovine viral diarrhea virus-hepatitis C virus 5' nontranslated region chimeras

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Poliovirus chimeras replicating under the translational control of genetic elements of hepatitis C virus reveal unusual properties of the internal ribosomal entry site of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Mutations in Hepatitis C Virus RNAs Conferring Cell Culture Adaptation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Hepatitis C virus replication in mice with chimeric human livers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Domains I and II in the 5' nontranslated region of the HCV genome are required for RNA replication

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Synthesis of a novel hepatitis C virus protein by ribosomal frameshift

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Mutation Master: profiles of substitutions in hepatitis C virus RNA of the core, alternate reading frame, and NS2 coding regions.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Genetic Analysis of Sequences in the 3' Nontranslated Region of Hepatitis C Virus That Are Important for RNA Replication

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

The 3'-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Eukaryotic initiation factor 4G-poly(A) binding protein interaction is required for poly(A) tail-mediated stimulation of picornavirus internal ribosome entry segment-driven translation but not for X-mediated stimulation of hepatitis C virus translat

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Emerging clinical applications of RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Antisense oligonucleotide inhibition of hepatitis C virus gene expression in transformed hepatocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Inhibition of hepatitis C virus replication by antisense oligonucleotide in culture cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Cleavage of viral RNA and inhibition of viral translation by hepatitis C virus RNA-specific hammerhead ribozyme in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Inhibition of hepatitis C virus (HCV)-RNA-dependent translation and replication of a chimeric HCV poliovirus using synthetic stabilized ribozymes

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

1 reference

7 January 2021

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

siRNA-directed inhibition of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Modulation of HIV-1 replication by RNA interference

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

RNAi could hold promise in the treatment of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Short interfering RNA confers intracellular antiviral immunity in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

RNA interference in adult mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Gene therapy. Intracellular immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Recent advances in the molecular biology of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

A second hepatitis C virus-encoded proteinase

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

In vitro study of the NS2-3 protease of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Mechanism of autoproteolysis at the NS2-NS3 junction of the hepatitis C virus polyprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

In vitro characterization of a purified NS2/3 protease variant of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides. Implications for control of viral processing

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

A collaborative screening program for the discovery of inhibitors of HCV NS2/3 cis-cleaving protease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Structure and function of the hepatitis C virus NS3-NS4A serine proteinase.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

A zinc binding site in viral serine proteinases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

On the size of the active site in proteases. I. Papain

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Mechanistic role of an NS4A peptide cofactor with the truncated NS3 protease of hepatitis C virus: elucidation of the NS4A stimulatory effect via kinetic analysis and inhibitor mapping

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Optimization of the P'-region of peptide inhibitors of hepatitis C virus NS3/4A protease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

1-Aminocyclopropaneboronic acid: synthesis and incorporation into an inhibitor of hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Alpha-ketoamides, alpha-ketoesters and alpha-diketones as HCV NS3 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Product inhibition of the hepatitis C virus NS3 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Peptide-based inhibitors of the hepatitis C virus serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: A 2.2 Å resolution structure in a hexagonal crystal form

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Biochemical and immunologic properties of the nonstructural proteins of the hepatitis C virus: implications for development of antiviral agents and vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

DExD/H box RNA helicases: from generic motors to specific dissociation functions

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

From RNA helicases to RNPases.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Structure of the hepatitis C virus RNA helicase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Modulation of hepatitis C virus NS3 protease and helicase activities through the interaction with NS4A

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

The hepatitis C viral NS3 protein is a processive DNA helicase with cofactor enhanced RNA unwinding

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Antiviral drugs: current state of the art.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

RNA-dependent RNA polymerases, viruses, and RNA silencing

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

1 reference

7 January 2021

Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Structural and functional insights provided by crystal structures of DNA polymerases and their substrate complexes.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Mechanism of action of foscarnet against viral polymerases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Current and future therapies of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Selective stimulation of hepatitis C virus and pestivirus NS5B RNA polymerase activity by GTP.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Phosphonoformate Inhibits Reverse Transcriptase

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Inhibition of hepatitis-B-virus DNA polymerase by phosphonoformate: studies on its mode of action

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Combination treatment for chronic hepatitis C: what is the role of ribavirin?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

VX-497: a novel, selective IMPDH inhibitor and immunosuppressive agent

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

Histamine in cancer immunotherapy: a preclinical background.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

In vitro effect of thymosin-alpha1 and interferon-alpha on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900069-7

7 January 2021

10.1016/S1089-3261(02)00069-7

Identifiers

DOI

1 reference

6 August 2017

1 reference